BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

Source: 
CP Wire
snippet: 
  • BioNTech will receive $120 million in upfront, equity and near-term research payments
  • Company is elligible for $305 million in additional payments
  • BioNTech has additional parnterships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health